External site

By following this link, you are leaving Medically and entering a website that is not owned or controlled by Roche. Roche does not take any responsibility for access to or use of this website, nor for any content therein.

Leave site
Home Oncology ESMO IO 2024
Roche and Genentech at

ESMO IO 2024

December 11 - December 13
Geneva, Switzerland / Virtual (Hybrid)
esmo.org
Add to calendar
Share feedback
Share page
-
Medical Materials
Agenda
Coming soon

Sign up or login to unlock the full suite of MEDICALLY features
Dec 12 / Roche and Genentech
SKYSCRAPER-06: EFFICACY AND SAFETY OF TIRAGOLUMAB PLUS ATEZOLIZUMAB PLUS CHEMOTHERAPY VERSUS PEMBROLIZUMAB PLUS CHEMOTHERAPY IN PATIENTS WITH ADVANCED NON-SQUAMOUS NON-SMALL CELL LUNG CANCER
Efficacy and safety of tiragolumab + atezolizumab + chemotherapy vs pembrolizumab + chemotherapy in patients with advanced non-squamous NSCLC from the Phase 2/3 SKYSCRAPER-06 study.
Oncology Lung Cancer ESMO-IO-2024

Sign up or login to unlock the full suite of MEDICALLY features
Dec 12 / Roche and Genentech
Strength of patient preference for atezolizumab subcutaneous vs intravenous for the treatment of NSCLC and subgroup exploratory analyses from the IMscin002 study
IMscin002: Exploratory analyses from the IMscin002 trial exploring patient strength of preference for atezolizumab subcutaneous vs intravenous for the treatment of NSCLC, according to baseline characteristics, number of injections, and injection duration.
Oncology Lung Cancer ESMO-IO-2024
12:30 PM
Duration 1hr Geneva, Switzerland
Strength of patient preference for atezolizumab subcutaneous vs intravenous for the treatment of NSCLC and subgroup exploratory analyses from the IMscin002 study
Majem M, Zvirbule Z, Korbenfeld E, Kolb-Sielecki J, Herraez-Baranda LA, Castro Sanchez AY Bustillos A, Liu X, Cappuzzo F
Oncology | Lung Cancer

You have successfully signed up for this alert. You will be notified when it is available.

Sign up or login to unlock the full suite of MEDICALLY features
Add to calendar
01:15 PM
Duration 5mins Room B
SKYSCRAPER-06: EFFICACY AND SAFETY OF TIRAGOLUMAB PLUS ATEZOLIZUMAB PLUS CHEMOTHERAPY VERSUS PEMBROLIZUMAB PLUS CHEMOTHERAPY IN PATIENTS WITH ADVANCED NON-SQUAMOUS NON-SMALL CELL LUNG CANCER
Socinski M, Rodriguez-Abreu D, Lee DH, Cappuzzo F, Nishio M, Lovly C, Ozyilkan O, Li Q, Johnson M, Garon E, Kilickap S, da Silva FAF, Alatorre-Alexander JA, Meng R, Rooney I, Troutman S, Wen P, Patil N, Zou W, Stahel R
Oncology | Lung Cancer

You have successfully signed up for this alert. You will be notified when it is available.

Sign up or login to unlock the full suite of MEDICALLY features
Add to calendar

This website is intended for healthcare professionals outside the United Kingdom (UK) and Australia. Registration status and prescribing information of medicinal products may differ between countries. Please refer to local product information for any medicinal products mentioned on this website.